CD74 and systemic lupus erythematosus: Additionally, in comparison with Telitacicept, a newly approved biologic for SLE that primarily suppresses B cell immune responses, Bud-ADC targets CD74 to broadly inhibit multiple immune cell types, which is theoretically expected to achieve greater efficacy and has demonstrated comparable therapeutic effects in SLE animal models.